<DOC>
	<DOCNO>NCT02565810</DOCNO>
	<brief_summary>A study compare use Pre-filled Pen Pre-filled Syringe SB5 Subjects Rheumatoid Arthritis .</brief_summary>
	<brief_title>An Multicentre Clinical Study Evaluate Usability Safety Pre-filled Pen Pre-filled Syringe SB5 Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1 . Are male female age 1855 year time signing informed consent form . 2 . Have diagnose RA accord revised 1987 American College Rheumatology ( ACR ) criteria least 6 month prior Screening . 3 . Subjects consider Investigator suitable candidate selfadministering adalimumab treatment 4 . Must able provide inform consent , must obtain prior study related procedure . 1 . Have treat previously biologic agent include tumour necrosis factor inhibitor . 2 . Have know hypersensitivity human immunoglobulin proteins component SB5 . 3 . Have current diagnosis active tuberculosis ( TB ) , recently expose person active TB , consider latent TB indicate positive QuantiFERON® Gold test result . 4 . Have serious infection ( sepsis , abscess , opportunistic infection invasive fungal infection include histoplasmosis ) treat intravenous antibiotic infection within 8 week oral antibiotic within 2 week prior first dose IP . Nonsignificant infection need consider exclusionary discretion Investigator . 5 . Have history chronic recurrent infection ( chronic renal infection , chronic chest infection recurrent urinary infection ) . 6 . Have follow condition : 1 . History congestive heart failure ( New York Heart Association Class III/IV ) 2 . History demyelinate disorder ( multiple sclerosis GuillainBarré syndrome ) . 3 . History malignancy ( lymphoproliferative disease melanoma , see Exclusion Criteria 10.f ) within previous 5 year prior Screening except completely excise cure squamous carcinoma uterine cervix , cutaneous basal cell carcinoma , cutaneous squamous cell carcinoma . 4 . History lymphoproliferative disease include lymphoma melanoma . 5 . Any disease disorder , opinion Investigator , put subject risk enrol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>